Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Inotek Pharmaceuticals Corporation

Latest From Inotek Pharmaceuticals Corporation

Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund

Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.

Financing Innovation

VC Exec Talks M&A And 2024 Expectations

VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.

VC Playbook Deals

Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ

Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.

Deal Watch Business Strategies

Panic Not, Say Analysts As Apellis’s Syfovre Launch Is Beset By Retinal Vasculitis Events

The US firm’s Syfovre for geographic atrophy due to age-related macular degeneration was linked with a handful of cases of occlusive retinal vasculitis, according to a letter published by a top retinal society, but most analysts believe there is a reasonable explanation.

Ophthalmic Safety
See All

Company Information